Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

2003 – Study shows Risperdal causes more hyperprolactinemia than other antipsychotics

Posted in Risperdal

A 2003 report by BJ Kinon et al. published in Psychoneuroendocrinology reports that risperidone (Risperdal) leads to elevated prolactin levels at a much greater rate than other antipsychotics.

Hyperprolactinemia, a condition characterized by elevated levels of prolactin – the hormone responsible for breast growth and milk production, carries with it a number of negative side effects including galactorrhea and gynecomastia – male breast growth.

Kinon et al. (2003) writing “The prevalence of hyperprolactinemia during treatment with conventional antipsychotic drugs or risperidone is under-recognized and requires further investigation”, this study team aimed to “determine the extent of this … problem”.

Studying 147 females (mean age 44.51 years) and 255 males (mean age 40.67 years), Kinon found that “The prevalence of hyperprolactinemia across all males (n=255) was 42.4%” and “The prevalence of hyperprolactinemia among females taking risperidone (N=42) was 88% versus 47.6% of those taking conventional antipsychotic drugs”.

As such, the team concluded that “Hyperprolactinemia is very prevalent among women and men treated with conventional antipsychotic medications or risperidone” and “Due to the adverse effects associated with hyperprolactinemia, this likelihood should be seriously considered when choosing an antipsychotic suitable for the patient.”

Sadly, the Risperdal Warning Label inadequately informs users of the risk for hyperprolactinemia and ensuing galactorrhea and gynecomastia.  As a result, a number of Risperdal gynecomastia lawsuits and other Risperdal lawsuits are currently being filed in great number.  If you or a loved one used Risperdal and suffered gynecomastia or another Risperdal side effect as a result, you may be entitled to significant financial compensation.

With the publication of this and other studies linking Risperdal and male breast growth, it is clear that the manufacturer of Risperdal (Janssen Pharmaceuticals, Inc.) knew, or should have known, the link between Risperdal and gynecomastia but failed to act.

For a free, no-obligation case consultation, contact our team of Risperdal lawyers at the information provided below.  We have the compassion, experience, and resources required to win the compensation you deserve.

Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our Risperdal Lawsuit Information page is a great place to start if you have any questions about Risperdal.